MET and non-small cell lung carcinoma: Basic science supported a key role of c-MET in NSCLC patients developing resistance to EGFR TKIs, supporting design of JNJ-61186372 (EGFR × c-MET BsAb) and patient selection criteria leading to demonstrated anti-tumor activity in NSCLC patients with resistance to EGFR TKIs (Park et al. 2020; Yun et al. 2020).